Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002006 | A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility | PHASE1 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Zidovudine | DRUG | - |
| Sargramostim | DRUG | - |
Inclusion Criteria Concurrent Treatment: Allowed: * Minimal local irradiation for tumors. Patients must have: * Diagnosis of AIDS or AIDS related complex (ARC). * Neutropenia, due either to zidovudine (AZT) or HIV infection. * Life expectancy = or \> 6 months. Exclusion Criteria Co-existing C...